Business Wire

Western Union Pays Tribute to First Responders & Essential Workers Globally

Share

Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement and payments, today announced a 50 percent fee reduction1 for front-line responders and essential workers sending money globally via any of the company's digital channels for the next two weeks. The promotion is a small tribute by the company to these customers for their endless commitment to their local communities and dedication to maintain the infrastructure and resources necessary to keep local economies afloat.

More than 65 percent of global citizens working and living across the world occupy roles as first responders or in essential service industries, according to Western Union’s business intelligence. These global citizens indexed high in such roles across major countries: 63 percent in the U.S.; 67 percent in the U.K; 68 percent in France; 70 percent in Germany; 62 percent in Australia; 58 percent in the UAE and 71 percent in Saudi Arabia.

“When the world stopped, our first responders and essential workers kept going,” said Western Union President and CEO Hikmet Ersek. “They have continued to show up, day after day, to make it possible for our communities and economies to carry on.”

“Many of the world’s frontline or essential workers are global citizens who regularly send money to loved ones back home. At Western Union, our inspiration comes from our customers who trust us with their hard-earned money. We want to acknowledge their dedication to keeping remittances moving to the communities and economies around the world that depend on them the most and support them as they continue promoting the health and safety of the communities around them.”

The fee reduction, valid with transfer code THANKS2020, applies to any transaction initiated in the majority of Western Union’s digital-enabled countries at westernunion.com or via the Western Union app, and received anywhere Western Union’s Global Network reaches: via bank account or wallet payout in more than 100 countries, as well as retail Agent locations in 200 countries and territories. The fee reduction will run from now until May 20, 2020 and is available to first responders representing medical, police, and fire department professionals as well as essential workers across food, transport, utility, and other essential industries, including manufacturing and construction.

Last month, Western Union announced the expansion of its digital money transfer services, the fastest-growing part of its business in 2019, to more than 75 countries. The end-to-end coverage ensures that these safe, convenient digital services are available to millions of the world’s most active money movers, especially during COVID-19. The company also last month announced, “Digital Location”, a phone-based concierge service meant to help customers complete digital transactions from the safety of their homes as well as home-delivery of remittance funds in some markets.

Western Union and the Western Union Foundation, along with partners, have pledged more than US$1.0 million in the fight against COVID-19. The foundation is prioritizing initiatives that include strengthening healthcare systems around the globe, serving vulnerable populations, including refugees and migrants. Additionally, the Foundation will continue to support local and global nonprofit organizations providing access to essential services, including hunger relief, medical training, education, supplies and equipment for frontline healthcare workers.

In addition, Western Union Business Solutions’ WU® NGO GlobalPay platform has enabled NGOs to focus on the vital work at hand delivering critical international operations to support communities in need. Since 2012, more than 2,000 NGOs have sent nearly $8 billion around the world in 132 currencies to more than 200 countries, through the platform.

All of Western Union’s responses and initiatives related to COVID-19 may be accessed via our dedicated Resource Center here.

WU-G

About Western Union 

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of March 31, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com.

Reference:

Western Union makes money on the foreign exchange conversion

Contact information

Western Union Global Communications
Pia De Lima; 
Pia.DeLima@westernunion.com
+1 (954) 260-5732

Western Union Americas
Margaret Fogarty; 
margaret.fogarty@wu.com

Western Union Middle East & Africa
Mohamed El Khalouki; 
Mohamed.ElKhalouki@wu.com

Western Union Asia-Pacific
Karen Santos; 
Karen.Santos2@westernunion.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom